The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model
PLOS Biology · 2026
DOI: 10.1371/journal.pbio.3003603 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2026. Verfasst von Zhihui Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Respiratory Infection and Intervention Laboratory of Frontiers Science Center for Disease-related…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lysosomes, Colorectal Neoplasms, Estradiol Dehydrogenases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, West China Hospital, Sichuan University, National Science Fund for Distinguished Young Scholars.
Abstract (Originalsprache)
The high prevalence of cancer immunotherapy resistance, coupled with substantial tumor heterogeneity, underscores the urgent need for innovative therapeutic targets. A deeper understanding of immunoregulatory mechanisms would provide new targets and combination therapeutic strategies for tumor therapy. In this study, we demonstrate that HSD17B12 enhances anti-tumor immunity and represents a promising therapeutic target. Mechanistically, HSD17B12 promotes lysosome-dependent degradation of PD-L1 via the VAC14 and ESCRT complexes across various malignancies, regardless of its 3-ketoacyl-CoA reductase activity. HSD17B12-deficient cells displayed PD-L1 accumulation in both tumor cells and exosomes, reducing T cell-mediated cytotoxicity. Notably, we found a significant negative correlation between HSD17B12 and PD-L1 expression in colorectal cancer tissues. Furthermore, high HSD17B12 expression in CRC correlated with increased infiltration of cytotoxic T cells. Based on these findings, we designed a peptide, HSD-CC1-NPGY, which effectively reduces PD-L1 expression in cells and suppresses tumor growth in a mouse model. Overall, our results establish HSD17B12 as an important regulator of anti-tumor immunity and a promising therapeutic target for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Respiratory Infection and Intervention Laboratory of Frontiers Science Center for Disease-related Molecular Network, and State Key Laboratory of Biotherapy, West China…
- National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Lunzhi Dai, Haiyan Ren
Förderung
- National Natural Science Foundation of China
- West China Hospital, Sichuan University
- National Science Fund for Distinguished Young Scholars
- the Young Scientists Fund of the National Natural Science Foundation of China
- the Sichuan Natural Science Foundation for Young Scientists
Zitieren
APA
Zhou, Z., Lu, Y., Li, P., Liu, X., Cheng, W., Chen, H. N., Dai, L., & Ren, H. (2026). The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLOS Biology. https://doi.org/10.1371/journal.pbio.3003603
Vancouver
Zhou Z, Lu Y, Li P, Liu X, Cheng W, Chen HN, et al. The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLOS Biology. 2026. doi:10.1371/journal.pbio.3003603
BibTeX
@article{Zhou2026,
author = {Zhou, Zhihui and Lu, Ying and Li, Pan and Liu, Xin and Cheng, Wei and Chen, Hai-Ning and Dai, Lunzhi and Ren, Haiyan},
title = {The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model},
journal = {PLOS Biology},
year = {2026},
doi = {10.1371/journal.pbio.3003603}
}
EUVIMED